Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis A Eichenauer

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
International Journal of Molecular Sciences|October 29, 2025
Prediction of Hyperinflammatory Phenotypes in Critically Ill Patients via Routine Clinical Data and IL-6: Towards Personalized Anti-Inflammatory TherapyCharlotte Linz, Alexander Shimabukuro-Vornhagen, Nina Hesse, et al.
British Journal of Haematology|January 24, 2021
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Horst Müller, Leonard Elger, et al.
Annals of Hematology|October 20, 2021
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospitalJorge Garcia Borrega, Jan-Michel Heger, Philipp Koehler, et al.
Hematological Oncology|August 14, 2024
Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single-center retrospective analysisMarie Anne-Catherine Neumann, Jan-Hendrik Naendrup, Jorge Garcia Borrega, et al.
Blood|June 17, 2010
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth, Lucia Nogová, Horst Mueller, et al.
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|September 19, 2022
[Team-specific impacts of the corona pandemic on intensive care medicine personnel of a maximum care hospital]Jochen Wolff, Jürgen Becker, Jan-Hendrik Naendrup, et al.
Leukemia & Lymphoma|October 22, 2013
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantBastian von Tresckow, Horst Müller, Dennis A Eichenauer, et al.
Leukemia Research|July 9, 2023
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysisJan-Michel Heger, Boris Böll, Jan-Hendrik Naendrup, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
International Journal of Molecular Sciences|October 29, 2025
Prediction of Hyperinflammatory Phenotypes in Critically Ill Patients via Routine Clinical Data and IL-6: Towards Personalized Anti-Inflammatory TherapyCharlotte Linz, Alexander Shimabukuro-Vornhagen, Nina Hesse, et al.
British Journal of Haematology|January 24, 2021
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Horst Müller, Leonard Elger, et al.
Annals of Hematology|October 20, 2021
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospitalJorge Garcia Borrega, Jan-Michel Heger, Philipp Koehler, et al.
Hematological Oncology|August 14, 2024
Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single-center retrospective analysisMarie Anne-Catherine Neumann, Jan-Hendrik Naendrup, Jorge Garcia Borrega, et al.
Blood|June 17, 2010
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth, Lucia Nogová, Horst Mueller, et al.
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|September 19, 2022
[Team-specific impacts of the corona pandemic on intensive care medicine personnel of a maximum care hospital]Jochen Wolff, Jürgen Becker, Jan-Hendrik Naendrup, et al.
Leukemia & Lymphoma|October 22, 2013
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantBastian von Tresckow, Horst Müller, Dennis A Eichenauer, et al.
Leukemia Research|July 9, 2023
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysisJan-Michel Heger, Boris Böll, Jan-Hendrik Naendrup, et al.
Pageof 13